期刊文献+
共找到39,949篇文章
< 1 2 250 >
每页显示 20 50 100
The Qilin Delivers a Jade Tablet to Confucius’Mother
1
《China Today》 2026年第2期69-69,共1页
Confucius’imminent birth is heralded by the appearance of the qilin.The mythical one-horned animal came to his mother at the door and cast out of its mouth a jade tablet bearing an inscription saying that she would g... Confucius’imminent birth is heralded by the appearance of the qilin.The mythical one-horned animal came to his mother at the door and cast out of its mouth a jade tablet bearing an inscription saying that she would give birth to“the son of the refinement of water,and that he would succeed the Zhou Dynasty,but as a king without a throne(su wang).”Stunned,Yan Zhengzai–Confucius’mother–tied an embroidered ribbon around the horn of the qilin,and the animal stayed for two nights. 展开更多
关键词 qilin refinement water mythical animal CONFUCIUS jade tablet zhou dynasty INSCRIPTION imminent birth
在线阅读 下载PDF
Analysis of the Efficacy of Short-Term Intensive Continuous Subcutaneous Insulin Infusion (CSII) Combined with Ganagliflozin Proline Tablets in Elderly Patients with Type 2 Diabetes Mellitus
2
作者 Hui Dai 《Journal of Clinical and Nursing Research》 2026年第2期286-291,共6页
Objective:To investigate the effects of switching to either Prandilin 25R monotherapy or Prandilin 25R combined with ganagliflozin proline tablets after short-term intensive continuous subcutaneous insulin infusion du... Objective:To investigate the effects of switching to either Prandilin 25R monotherapy or Prandilin 25R combined with ganagliflozin proline tablets after short-term intensive continuous subcutaneous insulin infusion during hospitalization in elderly patients with type 2 diabetes mellitus on glycemic control,glycometabolic indicators,and cardiovascular risk factors,and to evaluate the safety of the two regimens.Methods:A total of 78 elderly patients with type 2 diabetes mellitus admitted to our hospital from January 2025 to September 2025 were selected and randomly divided into a control group and an observation group,with 39 cases in each group.The control group received monotherapy with insulin lispro protamine recombinant injection(Prandilin 25R)after intensive continuous subcutaneous insulin infusion,while the observation group received Prandilin 25R combined with ganagliflozin proline tablets.Continuous glucose monitoring(CGM)was performed for 14 days during the intensive continuous subcutaneous insulin infusion therapy phase in the hospital,followed by routine fingertip blood glucose monitoring after 14 days.Glycemic control indicators,glycometabolic indicators,and the incidence of adverse reactions were compared between the two groups.Results:After treatment,the mean amplitude of glycemic excursions and the 24-hour blood glucose standard deviation were significantly lower in the observation group than in the control group,while the time spent within the target blood glucose range was significantly higher(p<0.05).The levels of glycated hemoglobin,fasting blood glucose,and 2-hour postprandial blood glucose were better in the observation group than in the control group;moreover,the body mass index,systolic blood pressure,and blood lipid levels improved more significantly in the observation group than in the control group(p<0.05).There was no statistically significant difference in the incidence of hypoglycemia between the two groups.Conclusion:Combination therapy with ganagliflozin proline tablets after short-term intensive continuous subcutaneous insulin infusion therapy can effectively improve glycemic variability in elderly patients with type 2 diabetes mellitus,with good safety.This suggests that ganagliflozin proline tablets have a hypoglycemic advantage in the combination regimen and possess high clinical promotional value. 展开更多
关键词 Type 2 diabetes mellitus Continuous subcutaneous insulin infusion Ganagliflozin proline tablets Glycemic variability
暂未订购
Integrated serum pharmacochemistry and network pharmacology validate Qiangli Dingxuan Tablets ameliorates metabolic hypertension via TLR4/MyD88/NF-κB pathway
3
作者 Jia-Yue Zhu Ying-Jie Dong +5 位作者 Ya-Wen Sun Min-Qiu Lin Fan Liu Jie Su Gui-Yuan Lv Su-Hong Chen 《Traditional Medicine Research》 2026年第8期1-14,共14页
Background:Modified Qiangli Dingxuan Tablets(ZYSJ)is an optimized formulation derived from the classic Chinese patent medicine Qiangli Dingxuan Tablet.It targets the pathological features associated with metabolic hyp... Background:Modified Qiangli Dingxuan Tablets(ZYSJ)is an optimized formulation derived from the classic Chinese patent medicine Qiangli Dingxuan Tablet.It targets the pathological features associated with metabolic hypertension(MH)and metabolic disorders,although its antihypertensive mechanism remains unclear.Methods:A rat model of metabolic hypertension was established using a high-sugar,high-fat diet combined with progressively increasing concentrations of ethanol.Blood pressure,serum lipids,inflammatory cytokines,and endothelial function markers were assessed.Serum pharmacochemistry combined with network pharmacology was employed to predict key targets and pathways,followed by in vivo validation using qRT-PCR,Western blotting,immunofluorescence,and immunohistochemistry.Results:ZYSJ significantly reduced blood pressure and serum lipid levels in model rats.Thirty absorbed bioactive components were identified.Mechanistic studies revealed that ZYSJ downregulated the TLR4/MyD88/NF-κB signaling pathway at both the mRNA and protein levels,upregulated endothelial nitric oxide synthase(eNOS)expression,and decreased the levels of inflammatory cytokines(TNF-α,IL-1β,IL-6),thereby improving vascular endothelial function.Conclusion:ZYSJ effectively lowers blood pressure and serum lipids in rats with metabolic hypertension.Its mechanism of action is closely associated with regulation of the TLR4/MyD88/NF-κB signaling pathway,improvement of vascular endothelial function,and alleviation of inflammation. 展开更多
关键词 metabolic hypertension Modified Qiangli Dingxuan tablets TLR4/MyD88/NF-κB signaling pathway serum-absorbed components herbal medicine
暂未订购
Efficacy and safety of Tripterygium wilfordii glycosides tablets combined with Western medicine for patients with rheumatic immune diseases
4
作者 Hang Shu Xiao-Yu Chen +2 位作者 Jie Zhao Pin Li Zhen Sun 《World Journal of Clinical Cases》 SCIE 2025年第6期14-23,共10页
BACKGROUND Rheumatic immune diseases are a group of chronic inflammatory diseases charac-terized by joint and systemic multi-organ involvement,including rheumatoid arthritis,systemic lupus erythematosus,and Sjogren’s... BACKGROUND Rheumatic immune diseases are a group of chronic inflammatory diseases charac-terized by joint and systemic multi-organ involvement,including rheumatoid arthritis,systemic lupus erythematosus,and Sjogren’s syndrome,among others.The pathogenesis of these diseases is related to the abnormal activation and regulatory imbalance of the immune system.The prevalence and morbidity of rheumatic immune diseases are high,imposing a significant burden on patients'quality of life and socio-economic costs.Currently,the treatment of rheumatic immune diseases mainly relies on Western medicine,such as non-steroidal anti-inflammatory drugs,glucocorticoids,disease-modifying antirheumatic drugs,and biologics.However,the therapeutic effects of Western medicine are not ideal,some patients poorly respond or are resistant to Western medicine,and long-term use often causes various adverse reactions.AIM To systematically evaluate the efficacy and safety of Tripterygium wilfordii gly-cosides tablets combined with Western medicine in the treatment of patients with rheumatic immune diseases.METHODS This study conducted a meta-analysis to systematically evaluate the efficacy and safety of Tripterygium wilfordii glycosides tablets combined with Western medicine for patients with rheumatic immune diseases.Chinese and English databases were searched for randomized controlled trials(RCTs)on the treatment of rheumatic immune diseases with Tripterygium wilfordii glycosides tablets combined with Western medicine.The quality of the included studies was assessed using the Cochrane risk of bias assessment tool.Meta-analysis was performed using RevMan 5.4 software.RESULTS The meta-analysis included 11 RCTs involving 1026 patients with rheumatic immune diseases.The combined treatment significantly reduced the risk of disease recurrence(relative risk=1.07,95%confidence interval:1.01-1.15,P<0.05)and showed no significant heterogeneity(I2=0%,P=0.53),indicating that Tripterygium wilfordii glycosides tablets combined with Western medicine is an effective method to reduce the possibility of postoperative recurrence in patients with rheumatic immune diseases.However,due to the limited number and quality of the studies included,these results should be interpreted with caution.CONCLUSION Tripterygium wilfordii glycosides tablets combined with Western medicine is an effective and safe treatment option for patients with rheumatic immune diseases and can be considered a clinical choice.However,more high-quality research is needed to validate this conclusion and provide more solid evidence for clinical practice. 展开更多
关键词 Rheumatic immune diseases Tripterygium wilfordii polyglycosides tablets Western medicine treatment Systematic review META-ANALYSIS
暂未订购
Efficacy and Safety Study of Rasagiline Tablets in the Treatment of Parkinson’s Disease
5
作者 Lu Zhang Jin Xu +1 位作者 Ling Liu Haiyan Tang 《Journal of Clinical and Nursing Research》 2025年第11期344-349,共6页
Objective:To evaluate the efficacy and safety of rasagiline tablets in the treatment of Parkinson’s disease,in order to provide a more scientific basis for the application of the drug in Parkinson’s disease.Methods:... Objective:To evaluate the efficacy and safety of rasagiline tablets in the treatment of Parkinson’s disease,in order to provide a more scientific basis for the application of the drug in Parkinson’s disease.Methods:This study is a single-arm,prospective,observational study.The trial collected patients with primary Parkinson’s disease who met the inclusion and exclusion criteria after being assessed by the investigator to evaluate the efficacy and safety of rasagiline tablets in the treatment of Parkinson’s disease patients through UPDRSIII and UPDRSII scales,and evaluated the efficacy and safety of rasagiline tablets in the treatment of Parkinson’s disease patients.Results:A total of 3560 patients were included in this study.44.1%of patients had early Parkinson’s disease,52.4%had intermediate Parkinson’s disease,and 3.5%had advanced Parkinson’s disease.The UPDRSIII(exercise capacity)score was 26.76 at baseline,25.47 at 1 month,24.18 at 2 months,and 23.39 at 3 months after treatment,and scores significantly improved over time(P<0.001).The UPDRSII(ability to perform daily living)score was an average of 23.60 at baseline,22.49 at 1 month,21.53 at 2 months,and 21.09 at 3 months after treatment,with statistically significant differences in scores between months(P<0.001).A total of 18 adverse events/reactions occurred in this study,and adverse symptoms eventually disappeared or resolved,without termination due to adverse events/reactions or patient discharge.Conclusion:Rasagiline tablets have significant efficacy in improving daily exercise capacity and living ability in patients with Parkinson’s disease,and have a certain safety,which supports the effectiveness of rasagiline as a treatment for Parkinson’s disease and provides new evidence for its clinical application. 展开更多
关键词 Parkinson’s disease Rasagiline tablets UPDRS score
暂未订购
Clinical Study on the Combination Therapy of Diosmin Tablets and Mayinglong Musk Hemorrhoids Ointment for Patients with Acute Hemorrhoids
6
作者 Quanchang Sun 《Journal of Clinical and Nursing Research》 2025年第6期286-292,共7页
Objective:To evaluate the clinical effect of combined therapy with Diosmin Tablets and Mayinglong Musk Hemorrhoids Ointment for patients with acute hemorrhoids.Methods:A total of 50 patients with acute hemorrhoids who... Objective:To evaluate the clinical effect of combined therapy with Diosmin Tablets and Mayinglong Musk Hemorrhoids Ointment for patients with acute hemorrhoids.Methods:A total of 50 patients with acute hemorrhoids who visited the hospital from January 2023 to January 2025 were selected as samples and randomly divided into two groups.Group A was treated with Diosmin Tablets combined with Mayinglong Musk Hemorrhoids Ointment,while Group B was treated with Mayinglong Musk Hemorrhoids Ointment only.The efficacy,wound recovery time,perianal pain score,hemorrhoid symptom score,and stress indicators were compared between the two groups.Results:The efficacy of Group A was higher than that of Group B(P<0.05).The postoperative perianal edema time and wound healing time in Group A were shorter than those in Group B,and the Visual Analog Scale(VAS)score was lower than that in Group B(P<0.05).The hemorrhoid symptom score in Group A was lower than that in Group B(P<0.05).The stress level in Group A was lower than that in Group B(P<0.05).Conclusion:The combination therapy of Diosmin Tablets and Mayinglong Musk Hemorrhoids Ointment for postoperative treatment of acute hemorrhoids can effectively relieve perianal pain,shorten the duration of hemorrhoids,and is highly feasible. 展开更多
关键词 Acute hemorrhoids Mayinglong musk hemorrhoids ointment Diosmin tablets EFFICACY
暂未订购
Effect of Bifidobacterium Triple Viable Bacteria Tablets on Neonatal Necrotizing Enterocolitis and Its Impact on Serum Factors of the Patients
7
作者 Xiaoyan Ding 《Journal of Clinical and Nursing Research》 2025年第8期292-297,共6页
Objective:To analyze the efficacy of Bifidobacterium triple viable bacteria tablets on neonatal necrotizing enterocolitis(NEC)and its impact on serum factors of the patients.Methods:From January 2021 to May 2025,88 ne... Objective:To analyze the efficacy of Bifidobacterium triple viable bacteria tablets on neonatal necrotizing enterocolitis(NEC)and its impact on serum factors of the patients.Methods:From January 2021 to May 2025,88 neonates with NEC admitted to our hospital were selected as study subjects.During the study,these 88 patients were evenly divided into two groups,namely the observation group and the control group,with 44 patients in each group based on the random number table method.In terms of treatment,the control group was treated with meropenem,while the observation group received additional treatment with Bifidobacterium triple viable bacteria powder based on the treatment plan of the control group.The clinical efficacy and differences in serum inflammatory factor levels between the two groups were compared.Results:The efficacy of the observation group(90.91%)was better than that of the control group(72.73%)(P<0.05).After treatment,the levels of C-reactive protein(CRP)and procalcitonin(PCT)in both groups decreased compared to those before treatment,and the values of the above indicators in the observation group were lower than those in the control group(P<0.05).Conclusion:Based on conventional treatment for NEC neonates,the use of Bifidobacterium triple viable bacteria tablets has significant efficacy and can effectively reduce serum inflammatory factor levels. 展开更多
关键词 Bifidobacterium triple viable bacteria tablets Necrotizing enterocolitis NEONATES Serum factors
暂未订购
Hypolipidemic effect and mechanism of Hedan tablet (荷丹片) based on network pharmacology
8
作者 HU Huiming WENG Jiajun +6 位作者 TANG Fangrui WANG Yaqi FAN Shengxian WANG Xuecheng CUI Can SHAO Feng ZHU Yanchen 《Journal of Traditional Chinese Medicine》 2025年第2期408-421,共14页
OBJECTIVE:To examine Hedan tablet(HDT,荷丹片)'s potential mechanisms in hyperlipidemic rats induced by a high-fat diet(HFD),as well as its regulatory effects and primary active constituents.METHODS:By using ultra-... OBJECTIVE:To examine Hedan tablet(HDT,荷丹片)'s potential mechanisms in hyperlipidemic rats induced by a high-fat diet(HFD),as well as its regulatory effects and primary active constituents.METHODS:By using ultra-performance liquid chromatography(UPLC)-quadrupole-time-of-flight(QTOF)-tandem mass spectrometry(MS/MS),the components of HDT that can enter the circulatory system were found,aiming to investigate its active constituents with pharmacological effects.Based on network pharmacology approaches,the relevant HDT targets in the therapy of hyperlipidemia were anticipated.The possible mechanism of HDT for hyperlipidemia treatment was verified by in-vivo experiments,and the main active components of HDT for hyperlipidemia treatment were analyzed via in-vitro experiments.RESULTS:UPLC-QTOF-MS/MS identified 30 components of HDT entering the circulatory system,primarily consisting of flavonoids,diterpenoids and alkaloids.The results of a network pharmacology study revealed that 30 active components mostly target 74 genes associated with hyperlipidemia.The primary active ingredients may include quercetin,kaempferol,and epicatechin,and the main gene targets may be tumor necrosis factor(TNF),interleukin-6(IL-6),interleukin 1 beta(IL-1β),etc.The results of animal experiments demonstrated that HDT can significantly regulate the blood lipid level in rats with HFD,improve the degree of inflammatory infiltration in rat liver cells,lower TNF-α,Creactive protein(CRP),IL-6,matrix metalloproteinase 9(MMP9) and malondialdehyde(MDA) levels while raising total superoxide dismutase(T-SOD) level.Meanwhile,HDT can considerably lower the expression of sterol regulatory element-binding transcription factor 2(SREBF2),3-hydroxy-3-methylglutaryl-CoA reductase(HMGCR),and MMP9 while significantly increasing the expression of peroxisome proliferator-activated receptor alpha(PPAR-α) and PPAR-γ.In vitro study confirmed that quercetin and kaempferol could reduce the levels of IL-6,IL1B,MMP9 and HMGCR in the high-fat model of hepatoma G2 cells.CONCLUSIONS:The mechanism by which HDT treats hyperlipidemia involves modification of the lipid metabolism targets such as downregulating SREBF2,HMGCR and MMP9,and upregulating PPAR-α and PPAR-γ,as well as anti-inflammatory and antioxidant actions.This study provides a pharmacological and biological rationale for the use of HDT in clinical hyperlipidemia management. 展开更多
关键词 HYPERLIPIDEMIA MECHANISM network pharmacology ultra-performance liquid chromatography-quadrupole-time-offlight-tandem mass spectrometry Hedan tablet
原文传递
Clinical Efficacy and Mechanism of Qinjin Tablet in Treating Unstable Angina with Phlegm-Stasis Syndrome Based on the HDL-C/MMP-9 Signaling Axis
9
作者 Yuan WANG Jingru GAO Hongjun ZHU 《Medicinal Plant》 2025年第6期49-53,63,共6页
[Objectives]To explore the clinical efficacy of Qinjin Tablet in treating unstable angina with phlegm-stasis syndrome and preliminarily explore its intervention mechanism.[Methods]Sixty unstable angina patients with p... [Objectives]To explore the clinical efficacy of Qinjin Tablet in treating unstable angina with phlegm-stasis syndrome and preliminarily explore its intervention mechanism.[Methods]Sixty unstable angina patients with phlegm-stasis syndrome were randomly divided into a treatment group and a control group(30 each).The control group received standardized Western medicine treatment,while the treatment group also took Qinjin Tablet.After a 4-week treatment,comparisons were made on improvement of angina symptoms,TCM syndrome scores,blood stasis scores,reduction/cessation of short-acting anti-angina drugs,Seattle Angina Questionnaire(SAQ)scores,blood lipid levels,and matrix metalloproteinase-9(MMP-9)concentrations between the two groups.[Results]No statistical differences existed in baseline data like age,gender,and disease duration between the two groups(P>0.05).The treatment group showed significantly better efficacy than the control group in improving angina symptoms,TCM syndrome scores,blood stasis scores,and reduction or discontinuation of short-acting anti-anginal drugs(P<0.05).The SAQ score increase was more significant in the treatment group(P<0.05).The control group significantly reduced low-density lipoprotein cholesterol(LDL-C)(P<0.05),while the treatment group markedly increased high-density lipoprotein cholesterol(HDL-C)(P<0.05).Post-treatment,the treatment group had a marked reduction in serum MMP-9(P<0.05),with no significant change in the control group.[Conclusions]Qinjin Tablet can significantly alleviate clinical symptoms and improve quality of life in UA patients by modulating the HDL-C/MMP-9 signaling pathway. 展开更多
关键词 Qinjin tablet Unstable angina Phlegm-stasis interlocking syndrome High-density lipoprotein cholesterol Matrix metalloproteinase-9
暂未订购
Exploring the mechanism of Shenhua tablet(肾华片)alleviating renal injury by regulating macrophage glycolysis via hypoxia-inducible factor-1α/pyruvate kinase M2 signaling pathway in diabetic kidney disease mice
10
作者 CHEN Yuanchun JING Jiaxing +5 位作者 LI Qingmin ZHOU Xiaohong JIN Xiaofei GAO Weijuan CHEN Xiangmei YU Wentao 《Journal of Traditional Chinese Medicine》 2025年第3期528-537,共10页
OBJECTIVE:To investigate the impact of Shenhua tablet(肾华片,SHT)on renal macrophage polarization and renal injury in mice with diabetic kidney disease(DKD)and to explore the potential mechanism involving the hypoxia-... OBJECTIVE:To investigate the impact of Shenhua tablet(肾华片,SHT)on renal macrophage polarization and renal injury in mice with diabetic kidney disease(DKD)and to explore the potential mechanism involving the hypoxia-inducible factor-1α(HIF-1α)and pyruvate kinase M2(PKM2)signaling pathway,along with the glycolysis metabolism pathway.METHODS:The animals were divided into the following groups:Model,Control,dapagliflozin,SHT low-dose,SHT medium-dose,and SHT high-dose.We assessed 24-hour urine protein(24 h-UTP)levels,urinary albuminto-creatinine ratio,and regularly monitored fasting blood glucose during the treatment period.After treatment,we examined renal tissue structure,renal function(urea nitrogen,uric acid,creatinine,cystatin C,β2-microglobulin),and glycolysis in renal macrophages.Additionally,we observed macrophage polarization in renal tissue and measured inflammatory factors(tumor necrosis factor-α,interleukin-1β,interleukin-6,interleukin-10,monocyte chemoattractant protein-1)to assess the immunoinflammatory status of the renal tissue.Finally,we investigated the expression of the HIF-1α/PKM2 signaling pathway in macrophages to explore its role in the glycolysis process.RESULTS:SHT shows a beneficial effect in treating DKD by reducing 24 h-UTP,regulating blood glucose levels,improving renal tissue structure,protecting renal function,inhibiting macrophage glycolysis,reducing macrophage transformation to the M1 state,and suppressing the expression of the HIF-1α/PKM2 signaling pathway.CONCLUSION:SHT may exert renoprotective effects by inhibiting macrophage glycolysis via the HIF-1α/PKM2 signaling pathway.This inhibition decreases macrophage M1 polarization and reduces immunoinflammatory injury in the renal tissue of DKD mice. 展开更多
关键词 diabetic kidney disease MACROPHAGES GLYCOLYSIS hypoxia-inducible factor-1α pyruvate kinase M2 Shenhua tablet
原文传递
A Case Study of Heart Failure Resulting from Dilated Cardiomyopathy Treated with Sacubitril Valsartan Sodium Tablets in Combination with Qiliqiangxin Capsules
11
作者 Qiuwen FU Li XU 《Medicinal Plant》 2025年第3期75-79,共5页
This article presents a case study of a 20-year-old male patient diagnosed with dilated cardiomyopathy(DCM)(NYHA IV).This condition was diagnosed as"heart failure disease"(water overflowing due to yang defic... This article presents a case study of a 20-year-old male patient diagnosed with dilated cardiomyopathy(DCM)(NYHA IV).This condition was diagnosed as"heart failure disease"(water overflowing due to yang deficiency,intermingled phlegm and stasis)in traditional Chinese medicine(TCM).The treatment approach employed a combination of TCM and Western medicine.Western medicine involved the administration of sacubitril valsartan sodium tablets to inhibit ventricular remodeling,in conjunction with diuretics and cardiotonic agents.Initially,TCM utilized a static infusion of Shenfu injection,which was subsequently supplemented with Qiliqiangxin capsules to invigorate qi,warm yang,activate blood circulation,and promote diuresis.After a follow-up period of 3 years,the patient's ejection fraction(EF)improved from 23%to 51%,and the left ventricular end diastolic diameter(LVed)decreased from 68 to 52 mm,accompanied by a significant alleviation of symptoms.These findings indicate that the combined treatment of TCM and Western medicine can synergistically enhance cardiac function and impede the progression of the disease,thereby offering valuable insights for the optimal management of DCM. 展开更多
关键词 DILATED cardiomyopathy (DCM) Heart failure Sacubitril VALSARTAN SODIUM tabletS Qiliqiangxin capsules Chest TIGHTNESS Shortness of BREATH
暂未订购
Application of Shexiang Baoxin Pill Combined with Rosuvastatin Calcium Tablets in the Treatment of Angina Pectoris due to Coronary Atherosclerotic Heart Disease
12
作者 Jingjiao Hui 《Journal of Clinical and Nursing Research》 2025年第11期230-236,共7页
Objective:To analyze the therapeutic efficacy of Shexiang Baoxin Pill combined with Rosuvastatin Calcium Tablets(ROS)in patients with angina pectoris due to coronary atherosclerotic heart disease(CHD-AP).Methods:Eight... Objective:To analyze the therapeutic efficacy of Shexiang Baoxin Pill combined with Rosuvastatin Calcium Tablets(ROS)in patients with angina pectoris due to coronary atherosclerotic heart disease(CHD-AP).Methods:Eighty CHD-AP patients admitted for treatment from January 2023 to December 2024 were selected and evenly divided using a random number table.The combined group(40 cases)received treatment with Shexiang Baoxin Pill combined with ROS,while the reference group(40 cases)received ROS monotherapy.The overall response rate,frequency and duration of AP attacks,blood lipid levels,and cardiac function indicators were compared between the two groups.Results:The combined group exhibited a higher overall response rate than the reference group.After treatment,the frequency and duration of AP attacks were lower in the combined group than in the reference group.Additionally,blood lipid levels and cardiac function indicators were superior in the combined group(p<0.05).Conclusion:The combination of Shexiang Baoxin Pill and ROS demonstrates favorable therapeutic effects in CHD-AP patients,effectively preventing AP attacks,regulating blood lipid levels,protecting cardiac function,and reducing disease risk. 展开更多
关键词 Shexiang Baoxin pill Rosuvastatin calcium tablets Coronary atherosclerotic heart disease Angina Pectoris
暂未订购
参郁宁神片(宁郁异形片)治疗轻度至中度抑郁症的随机、双盲、安慰剂/盐酸氟西汀对照、多中心Ⅲ期临床试验
13
作者 赵阳 曾美桦 +3 位作者 杨巧宁 高洪阳 李涛 高蕊 《中国新药杂志》 北大核心 2026年第3期318-324,共7页
目的:评估参郁宁神片(宁郁异形片)治疗轻度至中度抑郁症患者的临床疗效和安全性。方法:采用多中心、随机、双盲双模拟设计,纳入572例符合中国精神障碍分类方案与诊断标准(The Chinese Classification of Mental Disorders, Third Editio... 目的:评估参郁宁神片(宁郁异形片)治疗轻度至中度抑郁症患者的临床疗效和安全性。方法:采用多中心、随机、双盲双模拟设计,纳入572例符合中国精神障碍分类方案与诊断标准(The Chinese Classification of Mental Disorders, Third Edition, CCMD-3)且基线汉密尔顿抑郁量表(Hamilton Depression Rating Scale, HAMD)-17评分为14~24分的受试者,随机分为3组:参郁宁神片组(2.4 g,tid,n=344)、盐酸氟西汀组(10 mg·d^(-1)首周,20 mg·d^(-1)后续7周,n=115)及安慰剂组(n=113),持续治疗8周。主要终点为HAMD-17评分自基线至第8周的组间差异,采用改良意向治疗分析集,与阳性药组进行非劣效性检验(非劣效界值=2.5),与安慰剂进行差异性检验。结果:治疗8周后,参郁宁神片组HAMD-17评分较基线降低(10.50±4.46)分,显著优于安慰剂组[(7.03±5.07),P<0.05],与盐酸氟西汀组(10.13±3.94)的组间差异为-0.25(95%CI[-1.18,0.68]),达到非劣效标准。安全性分析显示,参郁宁神片组未报告药物相关不良事件(0%vs盐酸氟西汀组8.8%)。结论:参郁宁神片在改善轻中度抑郁症状方面呈现与盐酸氟西汀相当的临床疗效,且具有更优的安全性特征。该结果为参郁宁神片在抑郁症治疗领域的应用提供了高级别循证医学证据。 展开更多
关键词 中成药 参郁宁神片 宁郁异形片 抑郁 临床试验
原文传递
雷诺嗪缓释片有关物质超高效液相色谱方法学建立与验证 被引量:1
14
作者 孙春艳 夏博 +1 位作者 周培培 王如伟 《中南药学》 2026年第1期243-248,共6页
目的建立雷诺嗪缓释片有关物质含量的超高效液相色谱(UPLC)测定方法。方法采用UPLC法,以Waters ACQUITY UPLC BEH C18(2.1 mm×100 mm,1.7μm)为色谱柱,以pH 7.0磷酸盐缓冲液为流动相A,乙腈-甲醇(V/V,75∶25)为流动相B,进行梯度洗脱... 目的建立雷诺嗪缓释片有关物质含量的超高效液相色谱(UPLC)测定方法。方法采用UPLC法,以Waters ACQUITY UPLC BEH C18(2.1 mm×100 mm,1.7μm)为色谱柱,以pH 7.0磷酸盐缓冲液为流动相A,乙腈-甲醇(V/V,75∶25)为流动相B,进行梯度洗脱,流速为0.4 mL/min,检测波长为225 nm,柱温为50℃,进样量为2μL。通过系统适用性、专属性、精密度、线性试验、准确度、溶液稳定性等试验研究,对雷诺嗪缓释片的有关物质方法进行验证。结果该方法学验证结果良好,各介质条件下,雷诺嗪、杂质C、杂质Bis(N-oxide)、杂质A、杂质2、杂质N-oxide在0.1~20μg/mL质量浓度范围内精密度、准确度、线性良好,供试品溶液在48 h内稳定。结论本方法能准确测定雷诺嗪缓释片中的有关物质的含量。 展开更多
关键词 雷诺嗪缓释片 杂质 超高效液相色谱法 方法学验证
原文传递
三七丹参片调控血管新生改善心肌缺血损伤的作用机制
15
作者 杨媛 陈正红 +3 位作者 杨仕琦 徐敏 陈新利 吴晖 《中国医院药学杂志》 北大核心 2026年第4期370-376,共7页
目的:探讨三七丹参片(Sanqi Danshen Tablets,SQDS)通过促进血管新生减轻心肌缺血损伤的药理作用机制,为冠心病、心肌梗死等心血管疾病的防治提供有效策略。方法:通过左冠状动脉前降支结扎法构建SD大鼠心肌缺血(myocardial ischemia,MI... 目的:探讨三七丹参片(Sanqi Danshen Tablets,SQDS)通过促进血管新生减轻心肌缺血损伤的药理作用机制,为冠心病、心肌梗死等心血管疾病的防治提供有效策略。方法:通过左冠状动脉前降支结扎法构建SD大鼠心肌缺血(myocardial ischemia,MI)模型,分为假手术组、模型组、SQDS不同剂量组(52.6、105.2、210.6 mg·kg^(-1))及阿托伐他汀钙组(8 mg·kg^(-1))。采用心电图机监测大鼠心电图Ⅱ导联ST段偏移值;2,3,5-氯化三苯基四氮唑染色观察心肌梗死面积;酶联免疫吸附法测定大鼠血清和心肌组织中肌钙蛋白-Ⅰ(cTnⅠ)、肌酸激酶同工酶MB(CK-MB)的水平,免疫荧光染色观察大鼠心肌组织中血小板内皮细胞黏附分子-1(PECAM-1/CD31)与α-平滑肌肌动蛋白(α-SMA)共染,以及CD31与番茄凝集素(Lycopersicon esculentum agglutinin,LEA)、5-乙炔基-2'-脱氧尿嘧啶共染的阳性表达率。结果:与假手术组相比,模型组大鼠ST段显著抬高,心肌梗死面积显著增加,血清及心肌组织匀浆中cTnⅠ、CK-MB水平显著升高(P<0.01)。与模型组相比,SQDS治疗后,大鼠ST段偏移值显著回落,梗死区面积明显缩小,血清及心肌匀浆中cTnⅠ、CK-MB水平显著下降(P<0.01)。免疫荧光染色显示,与假手术组相比,模型组CD31/α-SMA及CD31/Edu/LEA共表达阳性率显著降低,SQDS治疗后上述指标共表达阳性率升高(P<0.05)。结论:SQDS可通过促进MI大鼠梗死区周边血管新生,改善心肌缺血。 展开更多
关键词 心肌缺血 血管新生 三七丹参片
原文传递
地榆升白片联合粒细胞集落刺激因子对儿童急性淋巴细胞白血病化疗后粒细胞缺乏的疗效
16
作者 刘志强 刘福稳 +1 位作者 卢娟 范小菊 《实用医学杂志》 北大核心 2026年第4期663-667,共5页
目的 探讨地榆升白片联合粒细胞集落刺激因子(G-CSF)对儿童急性淋巴细胞白血病化疗后粒细胞缺乏的效果。方法 选取2022年1月至2024年1月在医院接受治疗化疗的148例急性淋巴细胞白血病患儿为研究对象,所有患儿均出现粒细胞缺乏。随机数... 目的 探讨地榆升白片联合粒细胞集落刺激因子(G-CSF)对儿童急性淋巴细胞白血病化疗后粒细胞缺乏的效果。方法 选取2022年1月至2024年1月在医院接受治疗化疗的148例急性淋巴细胞白血病患儿为研究对象,所有患儿均出现粒细胞缺乏。随机数字表法将患儿分为观察组和对照组,每组74例。对照组接受G-CSF治疗,观察组在对照组的基础上联合应用地榆升白片。记录患儿rhG-CSF用药剂量及用药时间。在用药后第4、8、14、21天检测外周血中白细胞(WBC)数、中性粒细胞(NE)数、红细胞(RBC)数和血小板(PLT)数,并比较两组用药前后的血清谷丙转氨酶(ALT)、谷草转氨酶(AST)、肌酐(Cre)和尿素氮(Urea)。记录骨痛、发热、皮疹等不良反应发生情况。结果 观察组的rhG-CSF用药剂量和用药时间均低于对照组;观察组在用药后第4、8、14、21天的WBC、NE、RBC和PLT均高于对照组,且用药后ALT、AST、Cre、Urea数值低于对照组(P<0.05)。两组不良反应情况相比,差异无统计学意义(P>0.05)。结论 地榆升白片联合G-CSF治疗儿童急性淋巴细胞白血病化疗后粒细胞缺乏,能更快提升外周血粒细胞水平,且对肝肾功能未见额外负担。 展开更多
关键词 急性淋巴细胞白血病 粒细胞缺乏 地榆升白片 粒细胞集落刺激因子
暂未订购
红花逍遥片联合常规疗法治疗乳腺炎的成本-效果分析
17
作者 陈雯 张然 +4 位作者 封昭 侯新 朱丽 吴东盼 任晓明 《临床药物治疗杂志》 2026年第1期55-60,共6页
目的评估红花逍遥片联合常规疗法治疗乳腺炎的经济性,以期为临床合理用药提供参考。方法系统检索中国知网、万方数据知识服务平台、维普资讯、中国生物医学数据库PubMed,Embase及Cochrane Library等中英文数据库中红花逍遥片治疗乳腺炎... 目的评估红花逍遥片联合常规疗法治疗乳腺炎的经济性,以期为临床合理用药提供参考。方法系统检索中国知网、万方数据知识服务平台、维普资讯、中国生物医学数据库PubMed,Embase及Cochrane Library等中英文数据库中红花逍遥片治疗乳腺炎相关文献,检索时限为建库至2024年11月30日。以常规疗法为对照,对红花逍遥片联合治疗乳腺炎的文献进行系统梳理和meta分析。基于决策树模型,从中国卫生系统角度出发,计算增量成本-效果比(ICER),并进行敏感性分析。结果基础分析显示,红花逍遥片联合治疗方案每多治疗1例有效的乳腺炎患者需多花费1014.84元,ICER值小于本研究的意愿支付阈值(2024年我国人均GDP)。敏感性分析显示研究结果较为稳健。结论对于乳腺炎患者,红花逍遥片联合治疗方案比常规治疗方案更具经济性。 展开更多
关键词 红花逍遥片 乳腺炎 成本-效果分析 药物经济学
原文传递
感冒退烧片中板蓝根的质量控制研究
18
作者 姜莲 程韬 +2 位作者 廖敏 陈雯 舒柯 《山东化工》 2026年第6期39-42,共4页
目的:建立完善感冒退烧片中板蓝根的质量控制方法。方法:采用薄层色谱法建立了制剂中板蓝根的定性鉴别方法;采用高效液相色谱法建立了制剂中(R,S)-告依春含量测定方法,流动相采用甲醇-0.02%磷酸溶液(体积比6∶94),流速设定为1.0 mL/min... 目的:建立完善感冒退烧片中板蓝根的质量控制方法。方法:采用薄层色谱法建立了制剂中板蓝根的定性鉴别方法;采用高效液相色谱法建立了制剂中(R,S)-告依春含量测定方法,流动相采用甲醇-0.02%磷酸溶液(体积比6∶94),流速设定为1.0 mL/min,检测波长设定为245 nm,柱温:30℃,进样量:10μL。结果:薄层色谱法能定性检出靛蓝、靛玉红等成分,且斑点清晰、分离度好、阴性无干扰;(R,S)-告依春在质量浓度范围为0.0020~0.0491μg/mL时线性关系良好(相关系数r=0.9999),平均回收率为103.08%(RSD=1.06%)。结论:所建立的方法操作简便、专属性强,结果准确,可有效控制感冒退烧片中板蓝根的质量。 展开更多
关键词 感冒退烧片 薄层色谱 高效液相色谱 板蓝根 (R S)-告依春
在线阅读 下载PDF
伏立康唑片仿制药与原研药疗效和安全性的倾向性评分匹配分析
19
作者 裴彤 王之舟 +1 位作者 董宪喆 张兰 《中国医院用药评价与分析》 2026年第3期288-290,294,共4页
目的:评价伏立康唑片仿制药与原研药在真实世界中的临床疗效和安全性。方法:采用回顾性队列研究方法,选取2019年6月至2023年5月于该院住院接受伏立康唑片治疗的患者为研究对象。以伏立康唑片仿制药治疗的患者为观察组,以伏立康唑片原研... 目的:评价伏立康唑片仿制药与原研药在真实世界中的临床疗效和安全性。方法:采用回顾性队列研究方法,选取2019年6月至2023年5月于该院住院接受伏立康唑片治疗的患者为研究对象。以伏立康唑片仿制药治疗的患者为观察组,以伏立康唑片原研药治疗的患者为对照组,通过倾向性评分匹配法,减小混杂因素导致的偏倚。比较两组患者治疗或预防侵袭性真菌感染的有效率、真菌清除率,并分层分析低蛋白血症患者和血液病恶性肿瘤患者的有效率;对比两组患者的不良反应发生率,评价集采品种和原研品种的安全性。结果:纳入有效性研究的患者有350例,其中观察组155例,对照组195例;经倾向性评分匹配法匹配成功93组,共186例。观察组、对照组患者的有效率分别为77.42%(72/93)、78.49%(73/93),微生物清除率分别为77.42%(72/93)、75.27%(70/93);观察组、对照组低蛋白血症患者的有效率分别为73.02%(46/63)、67.21%(41/61),观察组、对照组血液病恶性肿瘤患者的有效率分别为81.08%(30/37)、82.93%(34/41),上述差异均无统计学意义(P>0.05)。纳入安全性研究的患者有473例,其中观察组226例,对照组247例;经倾向性评分匹配法匹配成功161组,共322例。用药期间,观察组、对照组患者的不良反应发生率分别为4.97%(8/161)、5.59%(9/161),差异无统计学意义(P=0.803)。结论:伏立康唑片仿制药与原研药在住院患者中治疗或预防侵袭性真菌感染的有效性和安全性相当。 展开更多
关键词 伏立康唑片 倾向性评分匹配 真实世界研究
暂未订购
华蟾素片联合仑伐替尼治疗Ⅲ、Ⅳ期肝细胞癌(热毒内蕴证)的效果
20
作者 孙畋 刘可期 谢超 《中国医学创新》 2026年第9期20-24,共5页
目的:探讨华蟾素片联合仑伐替尼治疗Ⅲ、Ⅳ期肝细胞癌(热毒内蕴证)的效果。方法:将2024年4月—2025年5月龙岩市第二医院收治的80例肝细胞癌(热毒内蕴证)患者,以随机数字表法分为对照组与观察组,其中对照组(n=40)以仑伐替尼治疗,观察组(n... 目的:探讨华蟾素片联合仑伐替尼治疗Ⅲ、Ⅳ期肝细胞癌(热毒内蕴证)的效果。方法:将2024年4月—2025年5月龙岩市第二医院收治的80例肝细胞癌(热毒内蕴证)患者,以随机数字表法分为对照组与观察组,其中对照组(n=40)以仑伐替尼治疗,观察组(n=40)在对照组的基础上联合华蟾素片治疗。两组均于治疗开始后12周评估疗效,比较两组肿瘤标志物、壳多糖酶3样蛋白1(CHI3L1)、中医证候积分、客观疗效和不良反应发生情况。结果:观察组癌症控制率较对照组高(P<0.05)。两组治疗前1 d肿瘤标志物、CHI3L1、中医证候积分比较,差异无统计学意义(P>0.05)。治疗开始后12周,两组癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、甲胎蛋白(AFP)、CHI3L1和中医证候积分(肝区疼痛、面色晦暗、脘腹胀满)降低,且观察组低于对照组(P<0.05)。两组高血压、疲乏、胃肠道反应等不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:华蟾素片联合仑伐替尼治疗肝细胞癌(热毒内蕴证),可降低患者的癌症标志物水平,改善症状,客观疗效好,安全性高。 展开更多
关键词 肝细胞癌 华蟾素片 仑伐替尼 肿瘤标志物
暂未订购
上一页 1 2 250 下一页 到第
使用帮助 返回顶部